Notice: Trying to access array offset on value of type null in /home/trinityn/public_html/wp-content/plugins/really-simple-facebook-twitter-share-buttons/really-simple-facebook-twitter-share-buttons.php on line 318
Follow
Cannabidiol, a compound found in marijuana, can mend fractured bones rapidly, according to a new study
Marijuana legalization is taking over, one state at a time. With 23 states having legalized it for medical use and four states for recreational use as well, marijuana is quite the center of attention.
As it should be, particularly as compounds extracted from the plant certainly benefit medical applications. The latest study on this matter suggests that fractured bones can be mended with the use of cannabinoid.
Other recent studies have placed marijuana as a top therapeutic tool for cancer, Parkinson’s disease, and PTSD. Albeit controversial in many states, scientific evidence that marijuana compounds are efficient in treating a large array of clinical problems cannot be denied.
And no, when medical researchers refer to marijuana as an excellent therapeutic tool, they don’t mean smoking a joint or gobbling down on marijuana candies or other products.
The new study looking at the effects of cannabidiol on fractured bones comes from Tel Aviv University. Cannabidiol is a marijuana non-psychotropic compound that enhances the process of bone fracture healing according to the researchers.
Published in the Journal of Bone and Mineral Research, the Tel Aviv University study explains how cannabidiol was isolated from THC, both being included in the cannabinoid class. The study was conducted on rats with fractured bones.
Injected in the rats, cannabidiol was observed to be able to mend the bones in eight weeks. Previous studies have also pointed to the beneficial effects of cannabidiol on hampering bone loss and aiding bone formation. Building on these findings, the lead researcher of the study, Doctor Yankel Gabet stated that future studies on the benefits of marijuana will certainly ensue.
His interest lies well within exploring the effects of marijuana that do not relate to getting sky-high, but could aid promoting further relaxation of marijuana regulations.
“The clinical potential of cannabinoid-related compounds is simply undeniable at this point. While there is still a lot of work to be done to develop appropriate therapies, it is clear that it is possible to detach a clinical therapy objective from the psychoactivity of cannabis. CBD, the principal agent in our study, is primarily anti-inflammatory and has no psychoactivity”,
stated Gablet.
In the U.S., there are 23 states that legalized medical marijuana. Another four have legalized marijuana for recreational use as well. Nonetheless, the industry is not as flourishing as it could be.
Foggy regulations and the ban at the federal level are hampering industry efforts and frustrating entrepreneurs and investors.
Although the situation seems poised to change. Republicans, traditionally opposed to any regulation on marijuana except for further enhancing the federal ban, are easing their stance.
The Compassionate Access, Research Expansion, and Respect States (CARERS) Act, introduced in March. The law has the potential to change the framework considerably: it would exclude persons who are acting within state law from the federal Controlled Substances Act.
At the same time, cannabis would go from schedule I classification to schedule II classification and cannabidiol would be separated from the definition of cannabis.
Photo Credits thedailychronic.ne
